• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aclaris raises $21M in Series A Financing

Aclaris raises $21M in Series A Financing

October 25, 2012
CenterWatch Staff

Aclaris Therapeutics, a privately held specialty pharmaceutical company focused on dermatological therapeutics, has secured $21 million in Series A financing.

The Series A, which will fund the development of a novel topical dermatological product, was led by Vivo Ventures and Fidelity Biosciences with participation from Sofinnova Ventures.

Dr. Neal Walker, a board-certified dermatologist and experienced entrepreneur, will lead Aclaris as CEO, president and director. Walker has co-founded a number of life-science companies and brings more than 18 years of pharmaceutical industry experience in R&D, regulatory affairs and business development to Aclaris. Most recently, he served as founder, CEO and director of Vicept Therapeutics, which was acquired by Allergan in July 2011. Walker also co-founded Octagon Research Solutions and served as its director until its recent acquisition by Accenture in August 2012.

"We brought together our experienced management team from Vicept to create a new company that will be focused on the development of therapeutics for dermatologists and their patients," said Walker. "We appreciate that our key former investors also support our vision for Aclaris and have funded this Series A financing to help us acquire and advance new therapeutics to the market."

Stephen Tullman, the former executive chairman of Vicept, will serve as chairman of the board of Aclaris. He currently serves as president and CEO of Ceptaris Therapeutics. In addition, Tullman is managing partner of NeXeption, a biotechnology management company formed to identify and acquire novel drug candidates that address unmet medical needs. Previously, he co-founded and led several companies including Ception Therapeutics, a biologics company that was acquired by Cephalon.

Albert Cha, M.D., Ph.D. and Ketan Patel, M.D., will also join the board of directors. Cha is a managing partner at Vivo Ventures, where he invests in private and public biopharmaceutical and medical device companies. Patel is a principal with Fidelity Biosciences, where he focuses on investing in private life sciences companies globally.

"Vivo is excited about Aclaris because we believe in the management team, the product, and continued need for novel dermatologic treatments," said Cha. "The Aclaris team has a proven track record of identifying and rapidly developing novel products that address unmet patient needs."

The Aclaris management team is rounded out with experienced leaders who also served with Walker at Vicept, including Christopher Powala as COO, Stuart Shanler, M.D., as CSO, Frank Ruffo as CFO and Brian Beger as vice president of clinical operations.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing